JP2025525989A - 感音性難聴の治療のためのｎｇｆの鼻腔内投与 - Google Patents

感音性難聴の治療のためのｎｇｆの鼻腔内投与

Info

Publication number
JP2025525989A
JP2025525989A JP2025507000A JP2025507000A JP2025525989A JP 2025525989 A JP2025525989 A JP 2025525989A JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025525989 A JP2025525989 A JP 2025525989A
Authority
JP
Japan
Prior art keywords
ngf
seq
mutant protein
concentration
hearing loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025507000A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024028487A5 (https=
JP2025525989A5 (https=
Inventor
カステッリ，ヴァネッサ
アラミニ，アンドレア
ブランドリーニ，ローラ
コッチアロ，パスクァーレ
ロメオ，ティツィアーナ
デッタ，ニコラ
アッパレンテ，ルチア
マッティオリ，シモーネ
カッターニ，フランカ
マンテルリ，フラビオ
アレグレッティ，マルチェッロ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2025525989A publication Critical patent/JP2025525989A/ja
Publication of JPWO2024028487A5 publication Critical patent/JPWO2024028487A5/ja
Publication of JP2025525989A5 publication Critical patent/JP2025525989A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2025507000A 2022-08-05 2023-08-04 感音性難聴の治療のためのｎｇｆの鼻腔内投与 Pending JP2025525989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22188990.0A EP4316505A1 (en) 2022-08-05 2022-08-05 Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP22188990.0 2022-08-05
PCT/EP2023/071698 WO2024028487A1 (en) 2022-08-05 2023-08-04 Intranasal administration of ngf for the treatment of sensorineural hearing loss

Publications (3)

Publication Number Publication Date
JP2025525989A true JP2025525989A (ja) 2025-08-07
JPWO2024028487A5 JPWO2024028487A5 (https=) 2026-04-20
JP2025525989A5 JP2025525989A5 (https=) 2026-04-20

Family

ID=82846594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025507000A Pending JP2025525989A (ja) 2022-08-05 2023-08-04 感音性難聴の治療のためのｎｇｆの鼻腔内投与

Country Status (7)

Country Link
EP (2) EP4316505A1 (https=)
JP (1) JP2025525989A (https=)
CN (1) CN119836297A (https=)
AU (1) AU2023317864A1 (https=)
CA (1) CA3263975A1 (https=)
IL (1) IL318657A (https=)
WO (1) WO2024028487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4659759A1 (en) * 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017120465A1 (en) * 2016-01-06 2017-07-13 Massachusetts Eye And Ear Infirmary Treating cochlear synaptopathy
WO2018140792A2 (en) * 2017-01-27 2018-08-02 Otonomy, Inc. Neurotrophin mutants for treating hearing loss and other otic disorders
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
CN119836297A (zh) 2025-04-15
EP4316505A1 (en) 2024-02-07
EP4565255A1 (en) 2025-06-11
IL318657A (en) 2025-03-01
CA3263975A1 (en) 2024-02-08
AU2023317864A1 (en) 2025-02-13
WO2024028487A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US12102692B2 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
US20230330268A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Yagi et al. Spiral ganglion neurons are protected from degeneration by GDNF gene therapy
JP2025525989A (ja) 感音性難聴の治療のためのｎｇｆの鼻腔内投与
Hu et al. NGF stimulates extensive neurite outgrowth from implanted dorsal root ganglion neurons following transplantation into the adult rat inner ear
CN110691607A (zh) 神经营养素用于治疗听力损失的用途
US20260048006A1 (en) Intranasal administration of bdnf for the treatment of sensorineural hearing loss
US20240382416A1 (en) Method of treating inflammation and photoreceptor cell degeneration in retinal degeneration patients
TWI856028B (zh) 治療聽神經病變異常族群疾病之方法
EP1547618B1 (en) Drug for auditory dysfunction
US12390510B2 (en) Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
US20240382461A1 (en) Pharmaceutical composition and method for prevention and treatment of hearing loss
US20110207689A1 (en) The treatment of hearing loss
WO2024164318A1 (zh) Gch1抑制剂在制备用于预防和治疗听力损伤的药物中的用途
WO2026050480A1 (en) Prevention of ag-induced hair cell death
HK40074395A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Galindo The effect of neurotrophic factors on spiral ganglion neurons
Banerjee et al. Otology and neuro-otology
HK40003977A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
PATRICIA et al. Long-Term Effects of Electrical
HK40003977B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK1262434B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260410